Expert Review of Pharmacoeconomics & Outcomes Research

Papers
(The H4-Index of Expert Review of Pharmacoeconomics & Outcomes Research is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Social care data in the UK; current landscape, challenges, and future recommendations36
How to create value with constrained budgets in oncological care? A narrative review23
Direct medical and indirect absenteeism costs among working adult ADHD patients in the United States21
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment19
Indication-based pricing of the pharmaceuticals in Croatia: case-study18
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology18
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia17
Adherence to augmentation therapy for the treatment of major depressive disorder16
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis13
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study13
The role of insurance policies in the drug pricing landscape12
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency12
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data12
0.056551933288574